ATAI Life Sciences

IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

Beckley Psytech Limited is a biotechnology company based in Oxford, United Kingdom, that develops psychedelic drugs aimed at treating psychiatric and neurological disorders. Founded in 2014, it focuses on harnessing the therapeutic potential of substances such as psilocybin to address significant mental health challenges, including depression and other debilitating neuropsychiatric conditions with considerable unmet needs. The company aims to integrate clinically validated psychedelic medicines into mainstream medical practices, offering patients innovative treatment options that differentiate from existing therapies. Through its drug pipeline, Beckley Psytech is committed to providing alternative solutions for those suffering from various mental health issues.

Beckley Psytech Limited is a biotechnology company based in Oxford, United Kingdom, that develops psychedelic drugs aimed at treating psychiatric and neurological disorders. Founded in 2014, it focuses on harnessing the therapeutic potential of substances such as psilocybin to address significant mental health challenges, including depression and other debilitating neuropsychiatric conditions with considerable unmet needs. The company aims to integrate clinically validated psychedelic medicines into mainstream medical practices, offering patients innovative treatment options that differentiate from existing therapies. Through its drug pipeline, Beckley Psytech is committed to providing alternative solutions for those suffering from various mental health issues.

IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

Psyber is a company focused on creating innovative interventions for various mental health disorders through brain-computer interface (BCI)-enabled digital therapeutics. By integrating BCI technology with psychedelics, Psyber develops devices that monitor electrical activity in the brain, allowing for real-time analysis of emotional, behavioral, and mental states. This approach aims to empower patients who are prescribed medication, facilitating changes in their feelings and behaviors to enhance their overall quality of life. Through its advanced therapeutic solutions, Psyber seeks to address the growing need for effective mental health treatment options.

IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.

Recognify Life Sciences is a biotechnology company focused on developing innovative treatments for cognitive impairment associated with schizophrenia. The company aims to transform the management of cognitive deficits by creating pharmaceutical therapies that modulate the excitatory and inhibitory balance in the brain. This approach is designed to enhance learning and memory, providing healthcare providers with new options to address cognitive impairment not only in schizophrenia but also in conditions such as Alzheimer's and other neurodegenerative and neurocognitive diseases. Recognify Life Sciences is dedicated to improving the quality of life for individuals affected by these challenging disorders.

COMPASS Pathways is a mental health care company based in Cheshire, United Kingdom, with operations in the United States. The company is focused on developing innovative therapies for treatment-resistant depression (TRD) using its proprietary psilocybin formulation, COMP360. Currently undergoing Phase IIb clinical trials, COMP360 aims to provide a new treatment option for patients who have not responded to traditional depression therapies. COMPASS Pathways emphasizes the combination of psilocybin-assisted therapy with psychological support to enhance treatment efficacy. The company is committed to addressing the significant unmet needs in mental health care by advancing evidence-based solutions for those suffering from mental health challenges.

Innoplexus AG is a technology company specializing in artificial intelligence and blockchain solutions aimed at enhancing decision-making across various industries, particularly in life sciences and finance. Founded in 2011 and headquartered in Eschborn, Germany, with additional offices in India and the United States, Innoplexus develops a range of products that facilitate real-time insights from both structured and unstructured data. Its life science solutions include Ontosight, which aggregates critical pharmaceutical information, and the Ontosight Xplore platform, designed for pre-clinical drug discovery. The company also offers a Clinical Trial Prediction Engine to forecast trial outcomes and a Data as a Service (DaaS) platform for accessing publicly available life sciences data. In the financial sector, Innoplexus provides AI-driven tools for risk management and compliance. Additionally, its academic solutions connect and contextualize data from public sources to support research. The company serves a diverse clientele, including pharmaceutical firms, biotechnology companies, financial institutions, and academic organizations.

Perception Neuroscience is a biopharmaceutical company dedicated to creating innovative therapies for neuropsychiatric conditions. The company's primary focus is on developing arketamine, an NMDA antagonist designed to offer effective treatment for serious psychiatric disorders. Arketamine has shown promise for its rapid-acting antidepressant properties and potential anti-suicidal effects, positioning the company at the forefront of advancing mental health treatment solutions.